technology
-
-
-
-
-
-

The U.S. Food and Drug Administration has approved Emcitate (tiratricol), the first FDA-approved treatment for patients with monocarboxylate transporter 8 deficiency, or MCT8 deficiency—also known as Allan-Herndon-Dudley syndrome. The September 28 decision gives adults and children with the ultra-rare X-linked disorder the first approved therapy aimed at the peripheral thyroid-hormone imbalance caused by the disease.…
-
-
-
-
-
-










